Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon

Cesare Mazzaro, Francesca Zorat, Consuelo Comar, Fabiana Nascimben, Dario Bianchini, Stefano Baracetti, Carlo Donada, Valter Donadon, Gabriele Pozzato

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. Only a small fraction of patients with hepatitis C virus (HCV) positive mixed cryoglobulinemia achieve longterm recovery after interferon (IFN) therapy; we evaluated the effectiveness and safety of combination therapy (interferon plus ribavirin) in nonresponders or those who relapsed after one or more courses of IFN. Methods. Twenty-seven patients with HCV positive mixed cryoglobulinemia were studied. All were treated with IFN-α2b (3 MU 3 times weekly) for one year, plus daily oral ribavirin 1000 or 1200 mg. Results. Five patients (18.5%) obtained complete recovery from viral infection and from all signs and symptoms of disease. During treatment, most patients (85%) improved clinically. All 5 responders were "relapsers" to the first treatment(s). Conclusion. Combination therapy of IFN plus ribavirin could be useful for patients with mixed cryoglobulinemia resistant to IFN as monotherapy.

Original languageEnglish
Pages (from-to)1775-1781
Number of pages7
JournalJournal of Rheumatology
Volume30
Issue number8
Publication statusPublished - Aug 1 2003

Keywords

  • α-Interferon
  • Hepatitis C virus
  • Mixed cryoglobulinemia
  • Non-Hodgkin's lymphoma
  • Ribavirin

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Fingerprint Dive into the research topics of 'Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon'. Together they form a unique fingerprint.

Cite this